Cargando…

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)

Detalles Bibliográficos
Autores principales:	Yellala, Amulya, Ganti, Apar Kishor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354154/ https://www.ncbi.nlm.nih.gov/pubmed/32676346 http://dx.doi.org/10.21037/tlcr.2020.04.12

Ejemplares similares

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Promising trends in lung cancer care, but are we overlooking the majority?
por: Sharma, Bhavina, et al.
Publicado: (2023)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
por: Arnold, Abram, et al.
Publicado: (2023)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Reade, Chad A, et al.
Publicado: (2009)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
por: Gower, Arjan, et al.
Publicado: (2022)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Current concepts in the management of small cell lung cancer
por: Ganti, Apar Kishor, et al.
Publicado: (2013)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database
por: Anggondowati, Trisari, et al.
Publicado: (2020)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
por: Almeldin, Doaa Said, et al.
Publicado: (2020)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

Small Renal Masses: The Evolving Histologic, Imaging, and Genomic Landscapes
por: Chavarriaga, Julian, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer
por: Reale, Maria Lucia, et al.
Publicado: (2020)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer
por: Keit, Emily, et al.
Publicado: (2021)

Cervical screening: the evolving landscape
por: Davies-Oliveira, Jennifer C, et al.
Publicado: (2022)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
por: Wang, Yanye, et al.
Publicado: (2020)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Implementing revised RED approaches to immunize in an evolving African landscape
por: Burgess, Craig Alexander
Publicado: (2017)

The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients
por: Germani, Marco Maria, et al.
Publicado: (2022)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Li, Fengtan, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response
por: Sehbai, Aasim, et al.
Publicado: (2022)

The evolving landscape in advanced penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2015)

The Evolving Landscape of Cardiovascular Disease Prevention
por: Cainzos-Achirica, Miguel, et al.
Publicado: (2021)

The evolving landscape of thoracic surgical oncology
por: Kim, Anthony W., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_re9bbbt65oq1osh6vuta6ov8rg